Pharmaceutical products

Tender description

NHS Framework Agreement for Adalimumab Injection Offer reference number: CM/PHR/19/5575 Period of framework agreement: 1 April 2020-31 March 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. NHS Framework Agreement for Adalimumab Injection Offer reference number: CM/PHR/19/5575 Period of framework agreement: 1 April 2020-31 March 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Products associated with the tender are listed on Document No 5 of the invitation to offer. There is no restriction on the number of products that bidders can offer for or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.